Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.
暂无分享,去创建一个
L. Schwartz | C. Porta | J. Bruix | A. Santoro | R. Finn | B. Daniele | M. Peck-Radosavljevic | L. Rimassa | J. Raoul | I. Borbath | G. Abbadessa | J. Trojan | A. He | T. Goldberg | M. Peck‐Radosavljevic
[1] Ryohei Katayama,et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. , 2013, Cancer research.
[2] Carmen Birchmeier,et al. Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.
[3] L. Jeng,et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Saijo,et al. Abstract 1639: The novel c-MET inhibitor, ARQ 197, shows additive growrh-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin/proteasome pathway , 2010 .
[5] J. Bruix,et al. Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design , 2013, Hepatology.
[6] D. Collins,et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Wen-Tsung Huang,et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). , 2013 .
[8] G. Braunstein,et al. Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells , 2013, Molecular Cancer Therapeutics.
[9] R. Wolff,et al. Assessment of the impact of systemic chemotherapy (SC) on the quality of life (QOL) in patients with metastatic unresectable appendiceal epithelial neoplasms (AEN). , 2013 .
[10] A. Zhu,et al. Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC) , 2012 .
[11] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[12] C. Porta,et al. Met as Prognostic Factor and Therapeutic Target in Pretreated Hepatocellular Carcinoma (HCC): Final Results of a Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197) , 2012 .
[13] L. Sequist,et al. Abstract 1729: An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study , 2012 .
[14] A. Rojnuckarin,et al. Abstract #820: Combination studies of tyrosine kinase inhibitors (TKIs): Assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinib , 2009 .
[15] U. Rix,et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. , 2014, ACS chemical biology.
[16] J. Sosman,et al. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. , 2012 .
[17] T. Tokuyasu,et al. Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance , 2013, Clinical Cancer Research.
[18] L. Sequist,et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Kudo,et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Jack Junjie Chan,et al. Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma , 2015, Diseases.
[21] A. Bardelli,et al. Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET , 2013, Clinical Cancer Research.
[22] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[23] R. Finn. Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now? , 2010, Clinical Cancer Research.
[24] W. Birchmeier,et al. Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.
[25] A. Jemal,et al. Global Cancer Statistics , 2011 .
[26] W. Ding,et al. c‐Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma , 2011, Hepatology.
[27] M. Kudo,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Bruix,et al. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis , 2013, British Journal of Cancer.
[29] A. Gasbarrini,et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.
[30] S. Jeay,et al. ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells , 2007 .
[31] J. Christensen,et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.
[32] J. Bruix,et al. Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter , 2013, Clinical Cancer Research.
[33] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[34] S. Jeay,et al. ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity , 2010, Molecular Cancer Therapeutics.
[35] S. Barni,et al. A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. , 2013 .